Thursday, May 22, 2025
5/22/2025
Mechanism and Countermeasure of Carfentanil-induced Respiratory Disorder and Death - PROJECT SUMMARY Opioids were involved in 75,673 overdose deaths in 2020 in the U.S, in which fentanyl, a synthetic opioid, is the deadliest due to induction of ventilatory depression. Carfentanil (CFN) is another synthetic opioid acting on opioid mu-receptors (MORs) with a potency 100 times that of fentanyl. Though no intending for therapeutic use, aerosolized CFN has been applied as a lethal agent (bioweapon) to cause respiratory disorder (RD) and death in humans. Naloxone increases survival rate of overdose opioids in early reports; however, deaths have been increasing after synthetic opioid era due to unsuccessful resuscitation attempts in clinical settings. It also fails to reverse aerosolized CFN-induced RD/death in animals. To date, the characteristics, mechanisms, and effective countermeasure of acute CFN exposure-induced RD/death are still unclear. Overdose fentanyl via intravenous (IV) perfusion produces RD including gradual ventilatory depression (dVE) and then apneas/gasping before death. The RD is believed to result from inhibiting the carotid body O2-receptor and central CO2-chemoreceptors, especially those in the retrotrapezoid and parafacial nucleus (RTN/PFN) and the respiratory neurons in the pre-Bötzinger complex (PBC, the respiratory rhythm-generator). Interestingly, we recently reported that IV bolus injection of fentanyl induced an immediate apnea solely mediated by bronchopulmonary C-fibers (PCFs) in anesthetized rats. Our pilot study further shows that the apnea is associated with closure of the larynx, constriction of chest expiratory muscles, and silence of inspiratory muscles (i.e., obstructive and central apnea with chest wall rigidity), which is lethal if overdosed. Moreover, aerosolized fentanyl (100 mg/m3 for 10 min) initially triggers the similar apnea followed by dVE and gasping, leading to death ~10 min post exposure in anesthetized rats. In this proposal, we, therefore, will characterize the cardiorespiratory (respiratory muscles’) responses to acute CFN exposure in awake rats and determine the causal roles of peripheral and central MORs (Aim 1). Subsequently, we will mechanistically demonstrate that CFN exposure stimulates PCFs to trigger the initial apneas and then inhibits the carotid body, RTN/PFN CO2-sensitive and PBC respiratory neurons to produce dVE and gasping (apneas) by acting on local MORs (Aim 2). Doxapram is a potent respiratory stimulant to the carotid body, while CX717 can enhance respiratory frequency and respiratory drive via acting on the PBC and strengthen central CO2-chemoreception. Both agents are capable of reversing opioid-induced RD in animals and humans. This, along with MOR internalization in vagal sensory neurons and blockade of IV injection of fentanyl-induced apnea by dermorphin pretreatment (a peripherally acting MOR agonist, IV) in our pilot study, allows us to define if a cocktail pretreatment of dermorphin, doxapram, and CX717 is a countermeasure for CFN-induced RD/death (Aim 3). A multidisciplinary approach (electrophysiology, immunohistochemistry, and pharmacology) at systemic and cellular levels will be employed to elucidate the mechanisms underlying acute CFN exposure-induced RD/death and evaluate the efficacy of the cocktail pretreatment. The expected data will, for the first time, mechanistically reveal the key roles of PCFs, the carotid body, RTN/PFN and PBC in generating the CFN-induced RD and provide a novel and potential countermeasure to prevent/diminish the RD/death.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).